Seed Round · Q1 2027
$1.5M to take a fully modeled computational platform into the lab, clear the two gates that decide whether the valve works, and reach a functional prototype.
- Round
- Seed
- Timing
- Q1 2027
- Amount
- $1.5M
- Pre-money
- $6M
- Post-money
- $7.5M
- Runway
- 18 months
The seed funds the move from model to measurement
Every computational phase is complete. The seed funds the transition to physical reality, and it starts with two biophysical measurements, each with a predefined success criterion, each run on standard instrumentation at an established core facility.
Both have clear failure paths with construct-level fixes already designed. When both clear, the same round carries the work through chassis construction and a prototype chip. We would rather tell you what we do not yet know than describe what we have modeled as though it were measured.
Validation Sequence
Both gates clear before any chassis or chip work begins. Strain engineering is the expensive step, and there is no reason to spend it before the valve protein is known to behave.
SEC-MALS on CompA_v3
Mw ≥ 1000 kDa, Mw/Mn < 1.5 (R_h ≥ 28 nm)
BLI/SPR — Jα motif to ePDZ anchor
K_d ≤ 1 µM lit, ≥10× dark/lit contrast
Six-gene chassis construction
PCR-verified knockouts
Valve function in hypha (microscopy)
Reversible reduction in cross-septal transport at 450 nm
Prototype chip colonization
Fluorescent flow through network
First academic beta site
LOI from 3 labs
G1 and G2 are gates. Everything below them has a dashed border because it is contingent on both clearing. No month numbers are given: a gated plan should not promise dates it cannot control.
$1.5M seed — 18 months to a functional prototype
Sivoro runs no lab of its own, so the largest line is contracted work at core facilities. Spend is sequenced against the gates: protein validation first, chassis and chip work after both clear.
| Category | Amount | % |
|---|---|---|
| Contracted lab & core facilities Core-facility access, SEC-MALS and BLI service contracts, consumables | $400k | 27% |
| Strain construction Contracted gene synthesis, cloning, and strain engineering · 18 months | $300k | 20% |
| Founder salary + ops 18 months runway | $250k | 17% |
| Protein validation E. coli / Pichia expression, purification, BLI/SPR | $200k | 13% |
| Chip prototyping SU-8 masters, PDMS, photomasks, microscope time | $150k | 10% |
| IP legal Non-provisional conversion + FTO · US + PCT option | $100k | 7% |
| Contingency (15%) Unforeseen costs | $100k | 7% |
| Total | $1,500k | 100% |
Next Round
Series A · $5M · Q4 2027
Scale production · Hire sales · Enter pharma pilots
Alongside the seed
Sivoro is also pursuing non-dilutive federal funding to support the validation gates. Any award would extend runway rather than replace the round.
Key Risks & Mitigations
Mitigation
Linker-length and fusion-terminus series, evaluated by the same assay (SEC-MALS). HEX1 oligomerization is well-characterized in the native protein; the open question is whether the fusion preserves it.
Mitigation
Motif-presentation series and an alternative sterically caged binding module. This is the highest-risk element of the program and our structure prediction is inconclusive (ipTM 0.18).
Mitigation
Morphological characterization precedes chip loading. Contingency: alternative promoters or partial truncations that preserve optogenetic response without a growth penalty.
Mitigation
Chassis work is sequenced after valve validation and does not gate it. Measured orthogonality is characterized before chip integration rather than assumed from the model.
Ready to Learn More?
Download the pitch deck, or reach out directly to schedule a conversation.
New York, New York · Seed round Q1 2027 · Pre-money $6M